International health agencies have promoted nontargeted universal (opt-out) HIV screening tests in different settings, including emergency departments (EDs). We performed a systematic review and meta-analysis to assess the testing uptake of strategies (opt-in targeted, opt-in nontargeted and opt-out) to detect new cases of HIV infection in EDs.
Introduction
Since the first case of AIDS was reported in 1981, more than 1 million people have been diagnosed with HIV infection and half a million have died from this condition in the USA [1] . It is estimated that approximately 156 300 infections remain undiagnosed and almost 50 000 people are newly infected each year [2] . An estimated 850 000 people are living with HIV in Western and Central Europe and it is estimated that 30% have not yet been diagnosed [3, 4] . In 2013, 136 235 new HIV infections were diagnosed in 51 countries of the World Health Organization (WHO) European Region [5] . New HIV infections represent missed opportunities for prevention and late diagnosis indicates missed opportunities for treatment. These situations are associated with increased morbidity and mortality, increased rates of HIV transmission, and increased health care costs [6] . In the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) European study (to which 84 524 individuals from 23 cohorts in 35 countries contributed data from 2000 to 2011), 53.8% of people were late presenters (CD4 count < 350 cells/lL) with HIV infection and 33.2% of them had advanced disease. A late presentation was associated with higher rates of AIDS/ death in the first year after HIV diagnosis among persons from Southern and Eastern Europe [7, 8] .
It can therefore be concluded that testing for HIV should be one of the main targets of initiatives aiming to control the epidemic, as it can reduce the rate of new infections [9] and allows prompt access to care and counselling. Early diagnosis of recent HIV infection is the best strategy to identify those individuals who are more contagious and gives the opportunity to treat them at very early stages of HIV infection.
Before 2006, the Centers for Disease Control and Prevention (CDC) recommended routine HIV testing for individuals at high risk for HIV infection. In 2006, the CDC revised its recommendations, advising health care providers to offer opt-out HIV testing as a part of routine medical services for all patients aged 13-64 years. The CDC adopted this HIV screening strategy because it enables HIV infection to be diagnosed before symptoms develop, the test is not expensive, infected patients gain years of life if treatment is initiated early, and the costs of screening are reasonable in relation to the benefit [10] . In 2007, the opt-out approach for HIV screening was integrated in the Joint United Nations Programme on HIV and AIDS (UNAIDS) and WHO guidelines [11] . Finally, the United States Preventive Services Task Force (USPSTF) revised its recommendations and extended HIV screening tests to teenagers and older people. The USPSTF recommends that HIV screening should be voluntary and the patients should be informed that HIV testing will be performed unless they decline (opt-out screening) [1] .
The ED provides an opportunity to test for HIV infection in patients who do not know their HIV status. Different testing programmes in terms of patient selection and the assay and consent mechanism used are implemented in EDs [12] .
Screening tests are offered through two strategies: targeted (HIV testing offered to patients with HIV risk factors) and nontargeted or universal (HIV testing offered to all patients). The screening strategies can require an indication that the patient wishes to be included (opt-in) or excluded (opt-out).
There are different strategies for HIV detection in Europe, varying from country to country and with the type of population. Several countries have adopted opt-out screening, but several places have a significant number of individuals who have not yet been screened.
From 2007 to 2008, a study conducted in six EDs in the USA found that none of the sites were able to test more than 10% of the patients presenting for care and none of the sites used the CDC's recommended opt-out approach to testing. However, it did conclude that HIV screening programmes were cost-effective [13] . In another prospective nested cohort study, opt-out screening was more costly but identified more HIV infections [14] .
The objective of this study was to perform a systematic review and meta-analysis to assess the testing uptake (the percentage of individuals newly diagnosed with HIV infection) in programmes with opt-in targeted, opt-in nontargeted and opt-out strategies among adult patients (excluding those who were pregnant) who attended EDs.
Methods
We searched the Pubmed and Embase databases, from 1984 to April 2015, for opt-in and opt-out HIV diagnostic strategies used in EDs, limiting the search to publications in the English language. We used the free text words as well as medical subject headings. We combined the following search terms and their variations: "HIV screening", "routine", "universal", "emergency", "opt-out" and "opt-in". We also examined the references of all included studies (see Appendices 1-5).
Inclusion criteria
We included cohort studies, cross-sectional studies, randomized controlled trials and quasi-experimental studies that reported the screening strategies (opt-in or opt-out) in EDs. We excluded modelling studies and cost-efficacy studies.
Study selection
Titles and abstracts were screened by two independent reviewers (CHC and PVG) who assessed the eligibility of articles. Discrepancies were resolved by a third independent reviewer (JEL).
Data extraction
Two reviewers using a standardized extraction sheet performed data extraction in duplicate. The following data were extracted: age of participants, year of study, intervention (opt-in or opt-out) and the prevalence of HIV diagnosis. The number of participants who were eligible to take the test and the number who were finally offered the test were obtained. For studies in which both strategies (opt-in and opt-out) were used, the results were analysed separately.
Quality assessment of included studies
The quality of included trials was assessed by CHC and PVG using the NewcastleÀOttawa Scale (NOS) [15] , which was modified to fit our study design: zero to three stars indicated poor study quality, four to six stars indicated acceptable study quality, and seven to nine stars indicated good study quality. In the event of disagreements, consensus was reached by discussion.
Statistical analysis
Data were analysed using STATA version 12 (StataCorp, College Station, TX, USA). We assessed publication bias by visually inspecting the forest plots, and performing an Egger test. We assessed the percentage of individuals tested for HIV in programmes with opt-in and opt-out strategies by combining studies in a random-effect metaregression model, using the arconsen double function [16] . We used a random-effect model for combining data where there was clinical heterogeneity sufficient to expect that the underlying effects differed between trials, or if substantial statistical heterogeneity was detected. We assessed statistical heterogeneity by examining the forest plots and using the I 2 and chi-squared statistics. We regarded heterogeneity as substantial if I 2 was > 30% or there was a low P-value (< 0.10) in the chi-squared test for heterogeneity. A sensitivity analysis was performed by iteratively removing one study at a time to determine how each individual study affected the overall estimate of the rest of the studies [17] . We attempted to explain any heterogeneity through subgroup analyses. We planned to conduct the following subgroup analysis: type of strategy (opt-in and opt-out) and type of opt-in strategy (nontargeted and targeted).
Results
We identified 46 potentially eligible full-text articles out of 90 identified studies based on titles and abstracts. Twenty-eight publications met our inclusion criteria but a further 18 articles were excluded (two were reviews, 10 did not meet inclusion criteria and four had incomplete data) (see Fig. 1 ). Four of the 28 included studies had two testing strategies (White et al. [18] had opt-out and opt-in nontargeted, Lyons et al. [19] had opt-in targeted and nontargeted, Haukoos et al. [20] had opt-in targeted and nontargeted, and Haukoos 2012 had opt-in nontargeted and opt-out). In our review, a publication bias was not detected, based on the funnel plot and the Egger test with P = 0.59 (see Appendix 2) . Quality assessment is provided in Appendix 3. The 28 studies included 148 736 patients who were tested. Two of the studies [21] and D' Almeida et al., 2012 [22] were carried out in France, Tan et al. [23] was carried out in Singapore, and the remaining 25 were carried out in the USA. We identified ten opt-out studies. All of the opt-out studies included adult patients, and three of them also included patients < 15 years of age. One opt-out study was a cohort study [24] and one was a cross-sectional study [25] . The remainder were prospective observational studies.
We identified 18 opt-in studies (opt-in targeted, two studies; opt-in nontargeted, 14 studies; and both strategies, two studies). All of the opt-in studies included adult patients, and six of them also included patients < 15 years of age. Only four opt-in studies were cross-sectional studies.
The trials included in the review were heterogeneous in terms of population and methods for patient inclusion. Also, the percentage of acceptance varied between studies within the opt-out and opt-in groups (Tables 1,  2 
and 3).
The test was offered to 172 237 patients in the opt-out group and 382 992 patients in the opt-in group (targeted: 6311 patients; nontargeted: 376 681 patients). The test was accepted and taken by 75 155 patients (44%) for the opt-out strategy, and 73 581 patients (4717 targeted and 68 864 nontargeted) (19%) for the opt-in strategy. The heterogeneity between screening strategies was high (Appendix 4). The test was refused by 97 082 patients (56%) in the opt-out group, and 309 411 patients (81%) in the opt-in group (targeted: 2852; nontargeted: 306 559).
In places where opt-out testing was performed (10 studies), new HIV infections were detected in 373 individuals (0.40%). In those where opt-in testing was performed (18 studies), new HIV infections were detected in 419 individuals (0.52%) for the opt-in nontargeted strategy, and in 52 individuals (1.06%) for the opt-in targeted strategy.
The testing uptake for the opt-in nontargeted strategy (the frequency of a positive test) to detect new cases of HIV infection, based on 16 studies, was 0.52% [95% confidence interval (CI) 0.31-0.76%]. The testing uptake for the opt-in targeted strategy to detect new cases of HIV infection, based on four studies, was 1.06% (95% CI: 0.24-2.10%). However, the heterogeneity was high (94% and 90%, respectively) (Fig. 2) . The prevalence of new cases of HIV infection detected by the two opt-in strategies combined (nontargeted and targeted), based on 20 studies, was 0.60% (95% CI of 0.39-0.85%).
The testing uptake for the opt-out strategy to detect new cases of HIV infection, based on ten studies, was 0.40% (95% CI: 0.21-0.64%).
Sensitivity analyses showed that the pooled effect size was not significantly different when any of the 3 trials with the less weight of effect was removed [25] [26] [27] .
Discussion
Our systematic review included over 125 979 individuals who attended the EDs in two countries (the USA and France). The results of the different studies were heterogeneous. The recruitment of the opt-out strategy was superior to that of the opt-in strategy, and the refusal rate was lower in the opt-out group, but the effect (number of new diagnoses of HIV infection) did not differ between the two groups. It is important to mention that most of the included studies were performed in the USA and informed consent was required for opt-out HIV testing. At present, written informed consent is not considered necessary at EDs for HIV testing in European countries.
There are, however, several limitations of this review. As noted previously, there were important differences between studies that led to heterogeneous results. Furthermore, the studies were conducted during a period in which HIV testing, treatment and prevention strategies were evolving rapidly. For example, the studies evaluating opt-out HIV testing were performed later than those with opt-in strategies, possibly leading to bias as a consequence of an increase in the level of HIV awareness and quality of care over time. Although in 2006 the CDC recommended opt-out HIV testing in health care settings, the majority of the included studies evaluated opt-in nontargeted strategies from 2007 onwards and some others evaluated limited opt-out strategies (Appendix 5).
At present, routine opt-out testing is advised in some diseases, such as tuberculosis. A Canadian study showed that, with the introduction of opt-out testing, the HIV testing rate increased (90 versus 26% before the introduction of opt-out testing), with a prevalence of newly diagnosed HIV infections of 5.6%. The patients with tuberculosis who were newly discovered to be HIV positive had more advanced HIV disease than non tuberculous patients. at diagnosis [28] . It is important to note that, since 1989, the CDC have recommended HIV testing for all patients with tuberculosis [29] .
Some studies carried out in EDs showed a lower impact of HIV testing in nontargeted populations compared with high-risk populations [30] . In a review of studies conducted between 2006 and 2013, 17 peer-reviewed studies were found to have reported the feasibility and effectiveness of nontargeted screening in EDs. In these studies, the proportion of individuals who completed testing was only 18% [31] .
A survey conducted in 24 European countries in September 2007 showed that routine testing in specific health care settings (in patients receiving antenatal care, patients with tuberculosis, patients with sexually transmitted infections and pregnant women) was used in the majority of countries. However, only 12 countries offered optout testing in settings other than antenatal clinics [32] .
While HIV testing may be carried out using different strategies, the objective of the current public health policy is to reduce the number of new infections. Therefore, it is important to detect potential carriers of the virus who are unaware of their infection status in a timely manner. There are benefits of early treatment both for the patient and for future susceptible individuals. The UNAIDS programme established, in December 2013, a new target for HIV treatment, with the aim of using the 90-90-90 strategy to avert about 60% of all new HIV infections by 2020 [33] .
Finally, current recommendations based on the studies published to date suggest that opt-out screening should be implemented in populations with a prevalence of undiagnosed HIV infection of ≥ 0.1% [1] . While other strategies have been effective in populations with a lower prevalence of HIV infection, EDs are settings where optin screening tests are probably more effective than in primary care, out-patient clinics or in-patient hospital settings. However, more prospective studies are needed to provide information that can be used to improve early detection and reduce the rate of new HIV infections.
Conclusions
In this meta-analysis, the testing uptake of the opt-out strategy was not different from that of the opt-in strategy to detect new cases of HIV infection in EDs. More randomized controlled trials are needed to determine whether a particular strategy is superior to the other in this setting.
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